Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

NS Pharma Develops First-of-its-Kind NS-089 NCNP-02 for Duchenne Muscular Dystrophy

NS Pharma has developed first-of-its-kind NS089/NCNP-02, an investigational candidate for individuals diagnosed with Duchenne muscular dystrophy (DMD) who could potentially benefit from exon 44 skipping therapy.

NS089/NCNP-02 is an antisense nucleotide, discovered through collaborative research between Nippon Shinyaku, and the National Centre of Neurology and Psychiatry.

The therapy aims to address the specific genetic mutation associated with Duchenne muscular dystrophy by skipping exon 44 during the production of dystrophin, a protein critical for muscle function.

NS089/NCNP-02 has the potential to restore the reading frame of the dystrophin gene, thereby potentially improving the production and function of dystrophin in patients with the relevant genetic mutation.

The clinical development of NS089/NCNP-02 involves planned Phase 2 studies, one to be conducted by NS Pharma in the United States and another to be conducted by Nippon Shinyaku in Japan. These studies are designed to assess the safety and efficacy of the investigational therapy in patients with Duchenne muscular dystrophy.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024